The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance-Reference-Cited by-同舟云学术

The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance

Published:2010-02-02 Issue:6 Volume:10 Page:489-504
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Reed K,Hembruff S L,Sprowl J A,Parissenti A M

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj20101.pdf

Reference49 articles.

1. Baker EK, El-Osta A . The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003; 290: 177–194.

2. Lehnert M . Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912–920.

3. Gottesman MM, Ambudkar SV . Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001; 33: 453–458.

4. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997; 3: 2025–2032.

5. Desiderato L, Davey MW, Piper AA . Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet 1997; 23: 391–400.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Regulation of Drug Transporters in Cancer;Drug Metabolism Handbook;2022-11-18

2. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells;Science Signaling;2022-08-30

3. P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease;Heliyon;2022-06

4. Unexpected gene activation following CRISPR‐Cas9‐mediated genome editing;EMBO reports;2021-12-20

5. Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line;Scientific Reports;2021-03-22